GLS logo

Gelesis Holdings (GLS) Stock

Profile

Full Name:

Gelesis Holdings, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 January 2022

Indexes:

Not included

Description:

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

May 12, 2023

Recent annual earnings:

Mar 24, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

20 Sept '22 Citigroup
Neutral

Screeners with GLS included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Royal Mail's sister business GLS to buy 20% stake in Greece's ACS for $80 million
Royal Mail's sister business GLS to buy 20% stake in Greece's ACS for $80 million
Royal Mail's sister business GLS to buy 20% stake in Greece's ACS for $80 million
GLS
reuters.com21 October 2024

Parcel services firm GLS, the international sister business to the UK's Royal Mail, has agreed to buy a 20% stake in Greece's ACS for 74 million euros ($80.06 million), their parent International Distribution Services said on Monday.

Royal Mail, GLS need sizable investments soon, billionaire suitor Kretinsky says
Royal Mail, GLS need sizable investments soon, billionaire suitor Kretinsky says
Royal Mail, GLS need sizable investments soon, billionaire suitor Kretinsky says
GLS
reuters.com29 May 2024

Royal Mail and its international parcels network GLS need sizable, almost immediate investments to defend market share and face shifting market trends, Czech billionaire Daniel Kretinsky told Reuters on Wednesday after the group's owner agreed to a 3.57 billion pound ($4.55 billion) takeover.

FAQ

  • What is the primary business of Gelesis Holdings?
  • What is the ticker symbol for Gelesis Holdings?
  • Does Gelesis Holdings pay dividends?
  • What sector is Gelesis Holdings in?
  • What industry is Gelesis Holdings in?
  • What country is Gelesis Holdings based in?
  • When did Gelesis Holdings go public?
  • Is Gelesis Holdings in the S&P 500?
  • Is Gelesis Holdings in the NASDAQ 100?
  • Is Gelesis Holdings in the Dow Jones?
  • When was Gelesis Holdings's last earnings report?
  • When does Gelesis Holdings report earnings?
  • Should I buy Gelesis Holdings stock now?

What is the primary business of Gelesis Holdings?

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

What is the ticker symbol for Gelesis Holdings?

The ticker symbol for Gelesis Holdings is NYSE:GLS

Does Gelesis Holdings pay dividends?

No, Gelesis Holdings does not pay dividends

What sector is Gelesis Holdings in?

Gelesis Holdings is in the Healthcare sector

What industry is Gelesis Holdings in?

Gelesis Holdings is in the Biotechnology industry

What country is Gelesis Holdings based in?

Gelesis Holdings is headquartered in United States

When did Gelesis Holdings go public?

Gelesis Holdings's initial public offering (IPO) was on 14 January 2022

Is Gelesis Holdings in the S&P 500?

No, Gelesis Holdings is not included in the S&P 500 index

Is Gelesis Holdings in the NASDAQ 100?

No, Gelesis Holdings is not included in the NASDAQ 100 index

Is Gelesis Holdings in the Dow Jones?

No, Gelesis Holdings is not included in the Dow Jones index

When was Gelesis Holdings's last earnings report?

Gelesis Holdings's most recent earnings report was on 12 May 2023

When does Gelesis Holdings report earnings?

The date for Gelesis Holdings's next earnings report has not been announced yet

Should I buy Gelesis Holdings stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions